Generic Name:
guselkumab
Project Status:
Complete
Therapeutic Area:
Psoriatic arthritis
Manufacturer:
Janssen Inc.
Brand Name:
Tremfya
Project Line:
Reimbursement Review
Project Number:
SR0733-000
NOC Status at Filing:
Post NOC
Details
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Tremfya (guselkumab injection) is indicated for the treatment of adult patients with active psoriatic arthritis. Tremfya can be used alone or in combination with a conventional disease-modifying antirheumatic drug (cDMARD) (e.g., methotrexate).
Submission Type:
Initial
Fee Schedule:
Schedule A
Tumour Type:
N/A
Indications:
Tremfya (guselkumab injection) is indicated for the treatment of adult patients with active psoriatic arthritis. Tremfya can be used alone or in combination with a conventional disease-modifying antirheumatic drug (cDMARD) (e.g., methotrexate).
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.